LONQURJA
Live / Allowed — Approved for publication (as of 01 Apr 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 25 Aug 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99356583
- Mark type
- Stylized text
- Filed
- 25 Aug 2025
- Attorney of record
- Jonathan M. Gelchinsky
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical and biological preparations for the treatment of hereditary angioedema (HAE); Pharmaceutical and biological preparations for treating and managing hereditary angioedema (HAE) and complications caused by hereditary angioedema (HAE); Pharmaceutical and biological preparations, namely, gene editing preparations for use with protein disorders and genetic diseases; Intravenous injectable gene therapy preparations for treating and managing swelling attacks; Therapeutic agents in the nature of CRISPR/Cas9 protein with guide RNAs targeting the KLKB1 gene to reduce production of plasma prekallikrein and control bradykinin generation
Owner
- Intellia Therapeutics, Inc., Cambridge, MA, US
Prosecution history
- 01 Apr 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Mar 2026 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 26 Mar 2026 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 26 Mar 2026 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 13 Jan 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 13 Jan 2026 — NON-FINAL ACTION E-MAILED
- 13 Jan 2026 — NON-FINAL ACTION WRITTEN
- 09 Jan 2026 — ASSIGNED TO EXAMINER
- 25 Aug 2025 — APPLICATION FILING RECEIPT MAILED
- 25 Aug 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 25 Aug 2025 — NEW APPLICATION ENTERED